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Background. Administration of safe and effective iron ther-
apy in patients with chronic kidney disease is a time consuming
process. This phase II clinical trial studied ferumoxytol, a semi-
synthetic carbohydrate-coated iron oxide administered by rapid
intravenous injection to anemic chronic kidney disease patients
(predialysis or undergoing peritoneal dialysis).
Methods. Inclusion criteria included hemoglobin ≤12.5 g/dL
and transferrin saturation ≤35%. Twenty-one adult patients
were randomized to receive ferumoxytol in a regimen of 4 doses
of 255 mg iron in 2 weeks or 2 doses of 510 mg iron in 1 to 2
weeks. Ferumoxytol was administered at a rate of up to 30 mg
iron/sec.
Results. The maximum hemoglobin response following feru-
moxytol administration occurred at 6 weeks, increasing from a
baseline of 10.4 ± 1.3 g/dL to 11.4 ± 1.2 g/dL (P < 0.05). Ferritin
increased from a baseline of 232 ± 216 ng/mL to a maximum
of 931 ± 361 ng/mL at 2 weeks (P < 0.05), while the baseline
transferrin saturation increased from 21 ± 10% to 37 ± 22%
at 1 week (P < 0.05). Seven adverse events in 5 patients during
this trial were deemed possibly related to ferumoxytol, none
serious. These events included constipation, chills, tingling, a
gastrointestinal viral syndrome, delayed pruritic erythematous
rash, and transient pain at the injection site.
Conclusion. Although larger studies are required, this small
study demonstrates that ferumoxytol can be safe and effec-
tive in increasing iron stores, is associated with an increased
hemoglobin response, and is well tolerated at a rapid infusion
rate.
Providing adequate bioavailable iron to patients with
chronic kidney disease (CKD) is necessary to ensure
an efficient response to erythropoietic hormone therapy
[1]. Additionally, there are data supporting a significant
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hemoglobin response in this population with parenteral
iron therapy alone [2]. Oral iron administration is rel-
atively ineffective in supporting erythropoiesis in CKD
patients [3–5], and many patients have gastrointestinal
intolerance of these compounds. As a result, intravenous
iron is commonly used to achieve and maintain adequate
iron levels in this patient population.
Until recently, iron dextran was the only intravenous
iron preparation available in the United States [6].
Adverse reactions have been reported in 4.7% to
43% of patients administered intravenous iron dextran
[7–9]. Most of these reactions are mild, with 38% of pa-
tients given a total dose infusion exhibiting delayed re-
actions of arthralgia, myalgia, and fever. Some patients
experience anaphylactoid-type reactions (defined as dys-
pnea, wheezing, chest pain, hypotension, urticaria, or an-
gioedema), which can be serious and life threatening [9].
Comparative data on the safety of the currently avail-
able parenteral iron preparations are difficult to evaluate
since information on the number of patients treated, the
specific product and dosage regimen utilized, previous ex-
posure to other iron preparations, and current diagnoses
are often not available. Reports are typically retrospec-
tive, and neither blinded nor comparative. A recent retro-
spective analysis concluded that the rate of adverse drug
events was lowest in patients receiving a low-molecular-
weight iron dextran preparation compared to a higher-
molecular-weight iron dextran or sodium ferric gluconate
[10].
Newer parenteral iron preparations such as sodium
ferric gluconate and iron sucrose are effective and
considered safer [11, 12], but require multiple and/or
relatively time-consuming administration regimens.
Currently, in the United States, according to the Food
and Drug Administration labeling, intravenous iron re-
placement is generally given as a slow infusion of 125 mg
sodium ferric gluconate over 10 minutes or 100 to 200 mg
of iron sucrose over approximately 5 minutes. These de-
livery modes incur significant expense for supplies, such
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as tubing and infusate, costly nursing time, and patient in-
convenience. To achieve iron repletion with these newer
agents, commonly a total dose of 1 g of iron requires 5 to
10 sessions over an extended period of time.
Ferumoxytol (Advanced Magnetics, Cambridge, MA,
USA) is an investigational, semi-synthetic carbohydrate-
coated, magnetic iron oxide preparation. It is one of a
class of compounds originally developed as magnetic res-
onance imaging (MRI) contrast agents, and is adminis-
tered for MR angiography as a rapid intravenous bolus
[13, 14]. Ferumoxytol was designed to minimize potential
immunologic reactions, such as those seen with commer-
cially available iron dextran products, and to minimize
free iron during dosing.
The purpose of this open label study was to evalu-
ate the safety and efficacy of ferumoxytol in stimulating
hemoglobin synthesis in anemic CKD patients on stable
dosing regimens of erythropoietic hormones.
METHODS
Subjects were recruited from 3 centers in the United
States for this prospective open-label phase 2 dose esca-
lation study. The primary purpose of the study was to
evaluate the safety of 2 dose regimens in this patient
population, while a secondary purpose was to gather ex-
ploratory data on efficacy to permit the design of larger
studies. The study was conducted in accord with the
Declaration of Helsinki and approved by an Institutional
Review Board for each site. After granting informed con-
sent, each subject had screening laboratory tests, a med-
ical history, and a physical examination performed to
establish a baseline and confirm inclusion criteria and
exclusion criteria. Patients included had been diagnosed
with CKD and could be on peritoneal dialysis therapy
but not hemodialysis. Other inclusion criteria included
an age of 18 years or greater, hemoglobin level less than
or equal to 12.5 g/dL, and a transferrin saturation of 35%
or less.
Exclusion criteria included women who were pregnant
or lactating, the use of parenteral or oral iron therapy
in the previous 2 weeks, transfusions or active bleed-
ing in the previous 2 months, major surgery within the
previous month, active infections, inflammatory condi-
tions, multiple drug sensitivities, autoimmune disease,
immunodeficiencies, androgen therapy within the past
12 weeks, iron overload (transferrin saturation 50% or
greater, serum ferritin 800 ng/mL or greater), severe hy-
perparathyroidism (parathyroid hormone greater than
1500 pg/mL), serum AST or ALT greater than 2 times
the upper limit of normal, and receipt of an investiga-
tional drug in the previous 30 days.
Patients were allowed, but not required, to be on ery-
thropoietic hormone therapy and the dose was allowed
to be modified in accordance with each site’s established
protocol for therapy.
Serum aluminum and parathyroid hormone concen-
trations and occult blood in the stool were determined at
screening. Serum chemistries, prothrombin time, and ac-
tivated partial thromboplastin times were obtained prior
to drug administration, and repeated one week follow-
ing completion of the dosing regimen. A complete blood
count and measures of body iron status (serum iron, to-
tal iron binding capacity, transferrin saturation, ferritin,
and transferrin) were obtained at screening and weekly
for 8 weeks following the first dose, using routine clinical
chemistry and hematology testing
The study drug, ferumoxytol (Advanced Magnetics,
Inc.), is a superparamagnetic iron oxide (magnetite)
nanoparticle coated with a semi-synthetic carbohydrate
designed to minimize immunologic sensitivity. The drug
has an average colloidal particle size of 30 nm by light
scattering and a molecular weight of 750 kD. Ferumoxy-
tol is a sterile liquid formulated to contain 30 mg/mL of
elemental iron and 44 mg/mL of mannitol. It is isotonic
and neutral pH.
Patients were to receive either 4 intravenous doses of
ferumoxytol at 255 mg of iron (group 1) or 2 intravenous
doses of ferumoxytol at 510 mg of iron (group 2). All
patients in group 1 were dosed and evaluated for safety
prior to enrolling any patients in group 2. Group 1 doses
were given every 2 to 3 days, while group 2 doses were
administered one week apart. An intravenous line (but-
terfly) was placed into a peripheral vein and 0.9% NaCl
was infused to keep the vein open. The appropriate dose
of ferumoxytol was administered by intravenous injection
into the peripheral vein at a rate of 1 mL/sec (30 mg/sec)
(i.e., 9 seconds for the 255 mg dose or 17 seconds for the
510 mg dose). A 10 to 20 mL normal saline intravenous
flush was given after drug administration.
Safety monitoring during drug administration included
measurement of blood pressure, heart rate, respiratory
rate, and oral temperature prior to drug administration,
and repeated at 15, 30, and 60 minutes after ferumoxy-
tol administration, as well as at weekly visits for 8 weeks
thereafter, along with evaluation for adverse events. Ad-
verse events were defined as illnesses, signs, or symp-
toms that appeared or worsened after the implemen-
tation of study procedures; evaluated as serious or not
serious; as mild, moderate, or severe; as definitely, prob-
ably, possibly, unlikely, or definitely not related to drug
administration.
Primary efficacy outcomes included changes from
baseline of hemoglobin, transferrin saturation, and serum
ferritin levels. The time to maximum response was evalu-
ated, as well as epoetin alfa and darbepoetin alfa dosing
regimens in the 4 weeks prior to and 8 weeks post feru-
moxytol administration. Safety data were gathered and
adverse events noted and evaluated for their association
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Table 1. Subject demographic and baseline clinical values
Dose groups
4 × 255 mg 2 × 510 mg Total
(N = 10) (N = 11) (N = 21)
Gender 4M/6F 5M/6F 9M/12F
Age 68.9 ± 10.4 58.0 ± 17.8 63.2 ± 15.4
(51–86) (28–78) (28–76)
Race (white/black/Hispanic) 9/1/0 7/3/1 16/4/1
Serum creatinine mg/dL 5.5 ± 4.2 3.2 ± 1.6 4.3 ± 3.3
(1.5–15.4) (0.6–6.0) (0.6–15.4)
Hemoglobin g/dL 10.9 ± 1.3 10.0 ± 1.3 10.4 ± 1.3
(8.8–12.6) (8.3–12.7) (8.3–12.7)
Ferritin ng/mL 252 ± 259 266 ± 215 232 ± 216
(74–782) (2–637) (2–782)
Transferrin saturation % 20.2 ± 7.3 21.0 ± 9.8 21 ± 10
(14–36) (3–35) (3–47)
GFR mL/min/1.73m2 15 ± 14 31 ± 31a 23 ± 25a
(4–38) (10–117) (4–117)
CKD stage 1/2/3/4/5 0/0/1/4/5 1/0/2/6/2 1/0/3/10/7
GFR, glomerular filtration rate, as estimated by the Modification of Diet in Renal Disease formula, (http://www.hdcn.com/calcf/gfr.htm). Values are given as mean ±
standard deviation. The range is stated in parentheses.
aOne patient with membranous nephropathy had a creatinine of 0.6 and GFR of 117. If this patient is excluded, the 2 × 510 group averages 23 ± 14 (10–53) and the
combined group is 19 ± 12 (4–53).
with ferumoxytol. Efficacy data were evaluated for each
individual dosing group as well as the combination of both
groups.
Statistics
All results are expressed as mean ± standard devi-
ation. Changes from baseline for the hematologic and
iron parameters were examined over time using one-way
repeated measures analysis of variance (ANOVA), with
post-hoc Dunnet’s test.
RESULTS
Twenty-one patients enrolled and completed this study,
18 of whom were predialysis CKD patients and 3 patients
(all in group 1) who were receiving chronic peritoneal
dialysis therapy. Of the 21 patients, 20 had a history of
hypertension, 14 with diabetes, and 2 with polycystic kid-
ney disease. The 10 patients in group 1 (4 × 255 mg iron)
received 40 doses of ferumoxytol and the 11 patients in
group 2 (2 × 510 mg iron) received 22 doses of feru-
moxytol. All patients completed dosing as planned. Pa-
tient demographics and baseline clinical characteristics
are presented in Table 1. Group 1 patients had a higher
hemoglobin (10.9 g/dL) at baseline than group 2 (10.0),
but this difference was not statistically significant.
Hematologic parameters and measures of iron status
are presented in Table 2, including baseline and maxi-
mal values, and the time in weeks at which the peak re-
sponse was observed. Since the 2 dosing groups received
the same total iron dosage, they were also combined
to form 1 group for statistical analysis. Changes in iron
status as reflected in ferritin and transferrin saturation
(Figs. 1 and 2) were maximal after 1 to 2 weeks, as was
the reticulocyte count, while hemoglobin and hematocrit
peaked later, at 5 to 6 weeks. Nine patients exhibited
transient ferritin values over 1000 (4 in group 1, 5 in
group 2). At 8 weeks after dosing was completed, 2 pa-
tients still had ferritin values greater than 1000, while the
other 7 patients had ferritin values that had decreased to-
ward baseline. The mean maximal change in hemoglobin
concentration (at 6 weeks after ferumoxytol administra-
tion) was 1 g/dL (Fig. 3). Although the 2 groups had
different baseline hemoglobin values, the hemoglobin
response was parallel and equivalent in magnitude.
Among the individual patients, 8 patients in each group
exhibited an increase in hemoglobin of greater than 0.5
g/dL. The maximum increase in reticulocyte count was
seen at 2 weeks.
In the 4-week period prior to ferumoxytol adminis-
tration, 13 of the subjects received stable hematopoietic
hormone therapy (10 subjects received epoetin alfa, 3
patients received darbepoetin alfa), while 8 subjects did
not receive either treatment (Table 3). In the 8 weeks af-
ter ferumoxytol dosing, 15 patients had their dosing regi-
mens unchanged, 4 patients had their mean weekly doses
decreased, and 2 patients had increases in their mean
weekly doses, 1 from 2000 to 3450 units (with no change
in hemoglobin concentration after ferumoxytol therapy)
and 1 from 10,000 to 20,000 units (with a maximal change
in hemoglobin post-ferumoxytol therapy of 0.7 g/dL, less
than the mean change in the 2 dosing groups). In patients
receiving epoetin alfa, the pre-ferumoxytol mean weekly
dosage was 9650 units, compared with the mean weekly
dose post-ferumoxytol dosage of 9100 units, not statis-
tically different. The mean weekly darbepoetin dosage
decreased from 30 lg to 27.8 lg after ferumoxytol ad-
ministration, not statistically different.
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Table 2. The hematologic and iron indices responses to ferumoxytol compared with baseline
Group Baseline Peak Time to peak
Hematocrit % 4 × 255 mg 33.9 ± 3.3 36.3 ± 2.2 6 weeks
(N = 10)
2 × 510 mg 30.3 ± 3.4 33.5 ± 3.8 5 weeks
(N = 11)
Total 32.0 ± 3.8 34.8 ± 3.4a 5 weeks
(N = 21)
Hemoglobin g/dL 4 × 255 mg 10.9 ± 1.3 11.8 ± 0.7 4 weeks
(N = 10)
2 × 510 mg 10.0 ± 1.3 11.0 ± 1.4 6 weeks
(N = 11)
Total 10.4 ± 1.3 11.4 ± 1.2a 6 weeks
(N = 21)
Reticulocyte count % 4 × 255 mg 1.8 ± 0.6 2.1 ± 1.0 2 weeks
(N = 10)
2 × 510 mg 1.7 ± 0.9 2.6 ± 1.4 2 weeks
(N = 11)
Total 1.74 ± 0.8 2.36 ± 1.3 2 weeks
(N = 21)
Ferritin ng/mL 4 × 255 mg 252 ± 259 988 ± 353a 2 weeks
(N = 10)
2 × 510 mg 212 ± 177 885 ± 378a 2 weeks
(N = 11)
Total 232 ± 216 931 ± 361a 2 weeks
(N = 21)
Transferrin saturation % 4 × 255 mg 20 ± 7 40 ± 8a 1 week
(N = 10)
2 × 510 mg 22 ± 12 35 ± 14a 2 weeks
(N = 11)
Total 21.3 ± 10 37.2 ± 22.1a 1 week
(N = 21)
a P < 0.05 compared with baseline value. None of the values for group 1 were different from those of group 2.
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Fig. 1. TSAT response to ferumoxytol.
The only statistically significant change in vital signs
was a decrease of the mean heart rate in the 4 × 255 mg
dose group from 73 to 68 following ferumoxytol dosing.
Routine serum chemistry values (apart from ferritin and
transferrin saturation) were unchanged in the postdose
observation period. There were a total of 7 nonserious
adverse events in 5 patients that were deemed possibly
related to ferumoxytol; no adverse event was considered
to be definitely or likely related, and none led to discon-
tinuation of dosing. These included solitary instances of
mild constipation a day later (group 1), mild chills an hour
after dosing (group 2), mild tingling a day after dosing
(group 1), moderate gastrointestinal upset of presumed
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Fig. 2. Ferritin response to ferumoxytol.
viral etiology a day after dosing (group 1), mild delayed
pruritic, erythematous rash 3 days after dosing (group 2),
and mild pain at the injection site that resolved after rein-
sertion of the intravenous line in a different site (group
2). No adverse event led to discontinuation of dosing.
DISCUSSION
Ferumoxytol was effective in rapidly increasing mea-
sures of body iron status (ferritin and transferrin satura-
tion), in both dosing groups, with a maximal effect seen
at 1 to 2 weeks. These increases demonstrate that the
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Fig. 3. Hemoglobin response to ferumoxytol.
iron contained in ferumoxytol is bioavailable, and is used
to promote increased hemoglobin synthesis and retic-
ulocytosis. Ferumoxytol administration was effective in
stimulating erythropoiesis without a significant increase
in dosage of hematopoietic hormone therapy, and in pa-
tients who had “normal” body iron stores (as evidenced
by the mean serum ferritin concentration of 232 ng/mL
and mean transferrin saturation of 21%). For the com-
bined groups there was a mean increase in hemoglobin
of 1 g/dL, maximally manifested at 6 weeks, while for the
individual dosing groups there was a similar and paral-
lel change. This is in keeping with the concept of func-
tional iron deficiency, seen frequently in patients with
chronic kidney disease, and which is responsive to ex-
ogenous iron.
This study demonstrates that ferumoxytol can be ad-
ministered as a rapid bolus of 30 mg of iron per second in
a concentrated form of 30 mg/mL, and in a dosage of up to
510 mg. In contrast, both iron sucrose and ferric sodium
gluconate require a much slower rate of administration
and/or much lower dose, mandating a longer period of
time and more clinic visits to administer equivalent doses.
Thus, ferumoxytol has the advantage of requiring fewer
patient visits and a shorter administration time than these
commonly used iron therapies, with benefit to the clini-
cian, ancillary staff, and patient.
A preparation of iron dextran, which was recalled by
the FDA in 1990, was the first available parenteral iron
preparation in the United States. Intravenous infusion
rates of 100 to 300 mg/min have been reported [15], al-
though subsequently a maximum rate of 100 mg/minute
was recommended [16]. Typical dosages reported ranged
from 500 to 3000 mg, although it is not clear how many of
the almost 2400 patients actually received (and tolerated)
the higher dosages/infusion rates. Since serious adverse
reactions to iron dextran may be induced by relatively
low doses, it is not possible to accurately describe serious
adverse reaction rates in this relatively small cohort.
Iron sucrose has been administered intravenously and
undiluted in dosages of 100 to 200 mg (5–10 mL) over a
5-minute period with relative safety, and in a dosage of
up to 500 mg diluted in 250 to 500 mL over a 2- to 6-hour
dosing duration [3–5, 12, 17–22]. One small, uncontrolled
study concluded that a regimen of iron sucrose 500 mg in-
travenously over a 2-hour duration had an unacceptably
high rate of adverse effects (e.g., hypotension requiring
hospitalization) [23]. In contrast, a study evaluating the
same dosing regimen in peritoneal dialysis patients noted
no adverse drug effects [18].
Sodium ferric gluconate has generally been diluted in
100 mL of 0.9% sodium chloride, at a dose of 125 mg,
and given intravenously over a 10-minute interval. Re-
cently, experience has been reported with 250 mg and up
to 500 mg dosages (not FDA approved), generally given
at slower administration rates (up to 5 hours). While one
study concluded that this could be done without appar-
ent adverse effects [24], others have noted significant
untoward reactions (e.g., severe nausea/vomiting, hy-
potension, and syncope) in 10% to 30% of patients with
this dosing regimen [25, 26]. If our data and experience
with ferumoxytol are confirmed in larger cohorts, feru-
moxytol would clearly represent an improvement in the
logistic aspects of intravenous iron delivery.
All adverse events considered possibly related to feru-
moxytol in this open label, uncontrolled study were mild
to moderate, and qualitatively similar to other iron prepa-
rations. No adverse event was serious, and none were
considered definitely or likely related to drug adminis-
tration. Anaphylaxis and immediate hypotension were
not observed in this small study, but the number of ex-
posures is too small to draw any definitive conclusions.
Other small studies of ferumoxytol in normal subjects,
hemodialysis patients, and patients undergoing cardio-
vascular MRI have reported nausea and metallic taste,
respectively [13; abstract; Jacobs P et al: J Am Soc Nephrol
14:27A, 2003].
The current study was of relatively short duration (less
than 12 weeks), and, thus, was not designed to address
the question of potential chronic toxicities of ferumoxy-
tol. With other parenteral iron preparations, the risks of
increased infection rates and oxidative stress have been
noted as possible toxicities. A recent review concluded,
however, that no studies exist that provide reliable con-
clusions linking parenteral iron therapy and infection in
dialysis patients [27]. While oxidative stress may be linked
to cardiovascular morbidity and mortality, careful mon-
itoring and avoidance of excessive serum ferritin levels
may minimize this risk [27].
CONCLUSION
Intravenous ferumoxytol in a dosage of up to 510 mg
can be given safely as a rapid intravenous bolus. It is ef-
fective in providing bioavailable iron to increase body
iron stores, as evidenced by improvements in ferritin and
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Table 3. Summary of erythropoietin dosing by dose group and time point
Ferumoxytol
Time point
Descriptive statistics 4 × 255 mg iron 2 × 510 mg iron Total
Baseline N = 10 N = 11 N = 21
Mean ± SD 7200.0 ± 8066.4 6272.7 ± 9381.8 6714.3 ± 8574.0
Day 7 (week 1) N = 10 N = 11 N = 21
Mean ± SD 7000.0 ± 8232.7 4090.9 ± 7435.8 5476.2 ± 7769.3
Change from baseline (mean ± SD) −200.0 ± 632.5 −2181.8 ± 12944.6 −1238.1 ± 9219.0
Day 14 (week 2) Not recorded N = 9 N = 10
Mean ± SD 6111.1 ± 9360.1 5500.0 ± 9033.9
Change from baseline (mean ± SD) −1555.6 ± 9043.1 −1400.0 ± 8540.1
Day 21 (week 3) N = 10 N = 9 N = 19
Mean ± SD 9245.0 ± 8015.3 3888.9 ± 7912.7 6707.9 ± 8215.8
Change from baseline (mean ± SD) 2045.0 ± 5590.5 −2666.7 ± 8000.0 −186.8 ± 7064.9
Day 28 (week 4) N = 10 N = 11 N = 21
Mean ± SD 7745.0 ± 8219.6 5000.0 ± 8729.3 6307.1 ± 8395.0
Change from baseline (mean ± SD) 545.0 ± 8788.5 −1272.7 ± 8112.8 −407.1 ± 8278.3
Day 35 (week 5) N = 10 N = 7 N = 17
Mean ± SD 7745.0 ± 8219.6 4428.6 ± 7345.2 6379.4 ± 7814.5
Change from baseline (mean ± SD) 545.0 ± 8788.5 −2000.0 ± 10392.3 −502.9 ± 9252.7
Day 42 (week 6) N = 10 N = 10 N = 20
Mean ± SD 4745.0 ± 6689.6 3000.0 ± 6342.1 3872.5 ± 6407.1
Change from baseline (mean ± SD) −2455.0 ± 6479.3 −1500.0 ± 8527.7 −1977.5 ± 7387.4
Day 49 (week 7) N = 10 N = 9 N = 19
Mean ± SD 4745.0 ± 6689.6 4444.4 ± 6839.4 4602.6 ± 6571.8
Change from baseline (mean ± SD) −2455.0 ± 6479.3 −555.6 ± 9837.6 −1555.3 ± 8059.3
Day 56 (week 8) N = 10 N = 6 N = 16
Mean ± SD 6795.0 ± 6467.3 3333.3 ± 8165.0 5496.9 ± 7093.2
Change from baseline (mean ± SD) −405.0 ± 5019.0 −2333.3 ± 11343.1 −1128.1 ± 7676.8
transferrin saturation, and in raising hemoglobin levels in
anemic CKD patients. Compared with other parenteral
iron preparations, it may provide efficiencies of time,
and perhaps cost, for patients and clinicians. Definitive
conclusions, including chronic toxicities, will be drawn
based upon the results of larger clinical trials, currently
in progress.
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